Table 2 Clinical and laboratory co-variates, therapy and outcomes of subjects with haematological cancer and COVID-19.

From: COVID-19 in persons with haematological cancers

 

Haematological cancer, N = 13

Health care providersa, N = 11

P value

Age, median (IQR), years

35 (23, 53)

32 (28, 36)

0.794

  Male sex

  

0.227

  Male

7

2

 

Signs and symptoms at onset

  Fever

12

4

0.008

  Cough

12

4

0.008

  Dyspnoea

10

3

0.043

  Muscle ache

1

0

>0.999

  Headache

1

0

>0.999

  Diarrhoea

3

2

>0.999

  Fever, cough and shortness of breath

8

3

0.205

Lung CT scan (N = 11)b

  Patchy shadows

2

2

>0.999

  Ground-glass opacity

8

9

 

  Air space consolidation/complete opacity

1

0

 

Laboratory findings (normal range), median (IQR)c

  WBC × 10E + 9/L (3.5–9.5)

3.9 (1.0, 9.4)

6.1 (5.3,.6)

0.470

  Neutrophils, ×10E + 9/L (1.8–6.3)

1.9 (0.4, 7.3)

4.1 (2.9,.5)

0.337

  Lymphocytes × 10E + 9/L (1.1–3.2)

0.5 (0.3, 0.9)

1.5 (1.2,.1))

0.012

  Platelets, ×10E + 9/L (125–350)

67 (24, 80)

247 (210, 274)

<0.001

  Haemoglobin, g/L (male, 130–175; female, 115–150)

69 (62, 89)

132 (125,134)

<0.001

  Prothrombin time, s (11–16)

16 (14, 17)

13 (12, 13)

0.105

  Activated partial thromboplastin time, s (28.0–43.5)

41.8 (34.2, 47.4)

28.8 (26.9, 30.6

0.0148

  D-dimer, mg/L (<0.5)

0.8 (0.6, 1.3)

0.5 (0.4, 0.7)

0.476

  Alanine aminotransferase, U/L (9–52)

17 (12, 27)

21 (17, 26)

0.799

  Aspartate aminotransferase, U/L (14–36)

23 (21, 32)

20 (19, 21)

0.496

  Total bilirubin, μmol/L (3–22)

11.1 (7.2,16.1)

9.4 (9.4, 9.4)

0.444

  Blood urea nitrogen, mmol/L (2.5–6.1)

4.7 (3.0, 6.5)

3.5 (3.3, 3.6)

0.476

  Serum creatinine, μmol/L (46.0–92.0)

47.4 (42.5, 69.8)

58.1 (54.7, 61.6)

0.800

  Lactate dehydrogenase, U/L (114–240)

246 (182, 313)

168 161, 175.5)

0.264

  Procalcitonin, ng/mL (<0.5)

1.5 (0.4, 3.7)

0.04 (0.03, 0.04)

0.022

  C-reactive protein, mg/L (<8.00)

68 (37, 126.0)

3.6 (2.5, 4.6)

0.001

Staging

  Mild

0

3

0.001

  Common

4

8

 

  Severe

4

0

 

  Critical

5

0

 

Co-infection

  Other viruses

7

0

0.006

  Bacteria

11

3

0.011

  Fungus

9

0

<0.001

Complications

  ARDS

6

0

0.016

  Acute renal failure

1

0

>0.999

  Sepsis

2

0

0.482

Treatment

  Umifenovir

8

7

>0.999

  Interferon

6

10

0.458

  Antibiotics

13

2

0.037

  Corticosteroids

4

2

0.649

  Oxygen

10

3

0.043

  Non-invasive ventilation

2

0

0.482

  Mechanical ventilation

1

0

>0.999

Outcomesd

  Cured

5

8

0.001

  Improved

0

3

 

  Stable

0

0

 

  Progressing

0

0

 

  Dead

8

0

 
  1. Data are N (%) unless specified.
  2. aHealth care providers with COVID-19.
  3. bLung CT scan data of subjects 1 and 5 were unavailable.
  4. cSubjects with haematological cancers and abnormal laboratory parameters were censored if seemed likely the abnormality was caused by anti-cancer therapies.
  5. dFollow-up date was 29 February, 2020.
Back to article page